Shown verbatim: the complete text as captured from the official PDF posted by the Oklahoma Legislature, fetched 2026-07-23. Page and line markers are part of the official record; nothing is edited or removed. The official bill page.
1 STATE OF OKLAHOMA
1
2 2nd Session of the 60th Legislature (2026)
2
3 SENATE BILL 1344 By: Rosino
3
4
4
5
5
6
6
7 AS INTRODUCED
7
8 An Act relating to prescription drugs; creating the
8 Insulin Access and Affordability Program for
9 specified purpose; directing the State Department of
9 Health to provide certain financial support;
10 requiring certain agreement with nonprofit
10 pharmaceutical manufacturer; describing agreement;
11 providing for codification; providing an effective
11 date; and declaring an emergency.
12
12
13
13
14
14
15 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
15
16 SECTION 1. NEW LAW A new section of law to be codified
16
17 in the Oklahoma Statutes as Section 1-271 of Title 63, unless there
17
18 is created a duplication in numbering, reads as follows:
18
19 A. There is hereby created the Insulin Access and Affordability
19
20 Program, which shall be administered by the State Department of
20
21 Health for the purpose of increasing patient access to affordable
21
22 insulin in this state, increasing marketplace competition, and
22
23 addressing shortages in the market for generic insulin.
23
24
24
Req. No. 2896 Page 1
1 B. The Department shall, with funds appropriated by the
1
2 Legislature, provide financial support to a nonprofit pharmaceutical
2
3 manufacturer that is currently developing a fast-acting biosimilar
3
4 insulin.
4
5 C. Prior to disbursement of any funds, the Department shall
5
6 enter into a memorandum of understanding (MOU) with the nonprofit
6
7 pharmaceutical manufacturer and the manufacturer shall demonstrate a
7
8 match of non-state funds equal to the amount provided under this
8
9 section. The MOU shall include:
9
10 1. A commitment by the manufacturer to produce a fast-acting
10
11 biosimilar insulin at a low net cost without rebates except as
11
12 required by law;
12
13 2. Estimated savings from the purchase of low-cost, fast-acting
13
14 biosimilar insulin including, but not limited to, the estimated
14
15 savings to residents of this state and public and private payors
15
16 from the availability of low-cost, fast-acting biosimilar insulin;
16
17 3. Provisions related to the repayment of the funds provided
17
18 under this section should the manufacturer fail to produce and
18
19 distribute a low-cost, fast-acting biosimilar insulin; and
19
20 4. Annual reporting by the manufacturer to the Department on
20
21 the development of the fast-acting biosimilar insulin.
21
22 SECTION 2. This act shall become effective July 1, 2026.
22
23 SECTION 3. It being immediately necessary for the preservation
23
24 of the public peace, health or safety, an emergency is hereby
24
Req. No. 2896 Page 2
1 declared to exist, by reason whereof this act shall take effect and
1
2 be in full force from and after its passage and approval.
2
3
3
4 60-2-2896 DC 12/30/2025 10:13:39 AM
4
5
5
6
6
7
7
8
8
9
9
10
10
11
11
12
12
13
13
14
14
15
15
16
16
17
17
18
18
19
19
20
20
21
21
22
22
23
23
24
24
Req. No. 2896 Page 3Every fact on this page links to its source, starting with the official bill record.